Visiongain Publishes Animal Antimicrobials and Antibiotics Market Report to 2031
12 March 2021
Visiongain has published a new report on Animal Antimicrobials and Antibiotics Market Report to 2031: Forecasts By Product Type (Penicillin, Tetracycline, Sulfonamides, Quinolones, Macrolides, Cephalosporin, Amingoglycoside, and Others), By Animal Type (Companion Animals and Food-producing Animals), By Mode of Delivery (Oral powder or solutions, Injections, Premix, and Others) PLUS COVID-19 Recovery Scenarios.
Global Animal Antimicrobials and Antibiotics market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.
COVID-19 Impact on Animal Antimicrobials and Antibiotics Market
The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the animal antimicrobials and antibiotics market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. The target market growth is expected to have an impact on the growing incidence of zoonotic infections, such as SARS-CoV-2 aka Covid-19, globally. There has been growth in animal health spending in current years, which is anticipated to push the target industry growth in the given time frame.
The High Growth of Livestock and Increased Intake of Milk and Other Food Products
The antimicrobial and antibiotic products have noteworthy advantages to human food safety and animals. Scientists have revealed that an increase in the frequency of animal illness perpetually results in a greater number of diseases among humans. Therefore, livestock dealers rely largely on animal antimicrobial and antibiotics to deliver non-toxic food. An additional factor fueling the target industry growth is the growing demand for milk, meat, and other food products. The use of several types of meats and a range of milk in dairy products, particularly in the western diet, and the prompt acceptance of these intake habits around the world are anticipated to lead to an increase in demand for animal antimicrobials and antibiotics worldwide.
Increasing Occurrences of Zoonotic Diseases
The increasing occurrence of zoonotic diseases in livestock is expected to help in the development of the target market. The rising prevalence of animal disease epidemics, a growing population of livestock, and favorable financial conditions of developing countries including Brazil, China, and India, are boosting the antimicrobials and antibiotics market growth. The outbreak of animal diseases, such as avian influenza or African swine fever is growing day after day, thus disturbing new areas too. Hence, decreasing possible risks by giving antibiotics to avoid infection spread is further boosting the animal antibiotics and antimicrobials market growth.
Growing Animal Health Expenditure
Spending on pet healthcare in the U.S. remains high. As per the American Pet Products Association (APPA), veterinary care is the second-highest source of expenditure. As per the APPA’s yearly expenditure figures, money spent on veterinary care totaled around $18.11 billion. In 2019, yearly expenditure is expected to be $18.98 billion. The APPA also says the frequency of veterinary appointments has likely amplified owing to lower cost, making pet care services more available to a larger population base. The reason behind this huge spending is the rise in the number of houses and American households own at least one pet. Also, veterinary technology has advanced significantly and complicated medical procedures have become easy and available to pet owners who are willing to pay for them. Thus, animal health expenditure is not going to decelerate any soon.
Key players operating in the global Animal Antimicrobials and Antibiotics market are Zoetis Inc., Vetoquinol, Elanco Animal Health, Merck And Co. Inc., Ceva Sante Animale, Bayer AG, Novartis AG, Virbac SA, Boehringer Ingelheim, Eli Lilly and Company and Sanofi.
The key players have adopted new product development, product launches, product approval, agreement, partnerships, and merger as its key business development strategies to tap into the global Animal Auto-Immune Disease Diagnostics market. For instance, on 6th November 2020, Agile Sciences and Stonehaven Incubate announced the opening of a new company intended at transforming the use of antibiotics in animal health.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033